Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 9, 2007
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancerJ-P Machiels, C Sempoux, P Scalliet, et al.
British Journal of Cancer|February 24, 2024
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD databaseC S Karapetis, H Liu, M J Sorich, et al.
British Journal of Cancer|April 20, 2022
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 studyE Van Cutsem, I Danielewicz, M P Saunders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2005
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCGD Nitti, J Wils, J Guimaraes Dos Santos, et al.
ESMO Open|February 22, 2025
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2S Stintzing, J Tabernero, T Satoh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2020
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 studyE Van Cutsem, I Danielewicz, M P Saunders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)M Moehler, A Maderer, P C Thuss-Patience, et al.
ESMO Open|February 13, 2026
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trialT Macarulla, R Pazo Cid, M S Womack, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2007
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015C-H Köhne, J De Greve, J T Hartmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2016
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patientsJ Taieb, R Balogoun, K Le Malicot, et al.
Pageof 23